P. Hemachandra Reddy, PhD | Texas Tech University Health Sciences Center

Ƶ

 

Hemachandra Reddy

P. Hemachandra Reddy, PhD

Professor, Department of Internal Medicine
Professor, Neurology and Neuroscience/Pharmacology


Reddy Laboratory - Research Website

 

P. Hemachandra Reddy, Ph.D., is the Tenured Professor and Vice Chair of Research of Basic and Translational Sciences Internal Medicine and Professor of Pharmacology & Neuroscience, Neurology, Public Health, and Speech, Language, and Hearing Departments at Texas Tech University Health Sciences Center in Lubbock. Dr. Reddy is also an adjunct Professor of the Nutritional Sciences Department of Human Sciences at Texas Tech University, Lubbock.       

Dr. Reddy’s scientific accomplishments cover a spectrum of neurologic disorders, with an emphasis on the role of mitochondria in Alzheimer’s disease (AD). Over the past two decades, he has firmly earned an international reputation for his work in aging, AD, and mitochondrial research. He has already received notable peer recognition. In 2014 he was elected a Fellow of the American Neurological Association (ANA. In 2020 he was elected as a Fellow of the American Association for the Advancement of Science Fellowship (F-AAAS) in the Biological Sciences category, where he was specifically recognized for his contributions to the understanding of the role of mitochondria in neurodegenerative diseases and their therapeutic targeting. In 2023 he was elected to the Sigma Xi Society, an honor society that recognizes scientific excellence. On December 12, 2023, Dr. Reddy was elected to the National Academy Inventors Fellows (NAI). Academic inventors and innovators are nominated to the rank of NAI Fellow status by their peers for making outstanding contributions to innovation in areas such as patents and licensing, innovative discovery and technology, significant impact on society, and support and enhancement of innovation. 

Dr. Reddy has published three Books with Elsevier – 1) Molecular Biology of Aging in 2017, 2) COVID-19 in Alzheimer’s Disease and Dementia in 2023, and  3. Co-edited/Published ebook ‘Interphase Between Aging and Neurodegenerative Diseases’, Published in 2020.

He was formerly an Executive Director and Chief Scientific Officer of the Garrison Institute on Aging (2014-2019) and a former Associate Scientist (2009-2014) in the Division of Neuroscience at the Oregon National Primate Research Center, affiliated with Oregon Health & Sciences University.

Dr. Reddy received his B.Sc. and M.Sc. in biology from Sri Venkateswara University, Tirupati, India, and he received an M. Phil in human cytogenetics from Delhi University. As a Commonwealth scholar (1990–1993), he was awarded a PhD (1994) in human genetics from the University College, London. Dr. Reddy received postdoctoral training (1995-2000) at the National Human Genome Research Institute of the National Institutes of Health. He was a standing member of the Veteran Affairs Merit Review Study Section (2007-2010), NIH study section, Neuronal Oxidative Metabolism and Death (2013-2019), and served on several NIH study sections. He received funding from NIH in 2002. Dr. Reddy is the Co-inventor and Chief Scientific Officer of Lubbock-based small business company, abSynapTEX, LLC. Recently, abSynapTEX, LLC received an STTR award from NIH. 

Dr. Reddy is a prolific writer, author, or co-author of more than 270 peer-reviewed articles/chapters/reviews, including publications in such journals as Nature Genetics, Redox Biology, Aging Cell, Ageing Research Reviews, Trends in Neurosciences, Trends in Molecular Medicine, Drug Discovery Today and Human Molecular Genetics. As indicated on the Google Scholar website https://scholar.google.com/citations?view_op=list_works&hl=en&user=AfziV3YAAAAJ (Google Scholar search), Dr. Reddy’s articles have received over 30,000 citations with an H-Index of 89 and an i10-Index of 200.

According to Expertscape website (2023), the expertise of P. Hemachandra Reddy ranks in the Top 0.0081% of 259,115 published authors worldwide on Mitochondria from 2013 through 2023 https://expertscape.com/au/mitochondria/Reddy%2C+P+H According to  Stanford University Academic Ranking, Dr. Reddy has been on the Top 1.5% World Researchers and #1 at  Ƶ-GSBS and in 2021, Dr. Reddy received Ƶ President’s Excellence in Research Award. 

In addition, he received several awards and honors including the Prestigious Bharath Gaurav Award (2016) from the Government of India; the Best Mentor Award (2003) and Technology Innovation Award (2007) from Oregon Health and Science University and the Alzheimer's Award (2006) from the Journal of Alzheimer's Disease and Fellows Award for Research Excellence (FARE Award) (1999) from National Institutes of Health. Dr. Reddy was honored as best neuroscientist for his contributions to neurology and brain disorders at the second International conference, in Rome, Italy June 3-6, 2018. 

Dr. Reddy received three United States patents for his lab discoveries:  a) D-1289 - Aqua-soluble DDQ Promotes Healthy Aging and Delays Progression of Alzheimer’s Disease in Humans), b) D-1417 - MicroRNA-455-3p as a Potential Peripheral Biomarker for Alzheimer’s Disease and c) D-1535 - Identification of novel circulatory microRNA signatures linked to patients with Ischemic Stroke. Several others are pending d) Synaptosomal microRNAs and synapse functions in Alzheimer’s disease, e) D-1294 - Mitochondrial Division Inhibitor 1 for the Treatment of Alzheimer’s Disease), f) D-1417 - MicroRNA-455-3p as a Potential Peripheral Biomarker for Alzheimer’s Disease), g) D-2019-066 - Phosphorylated Tau Inhibitors for treatment of Alzheimer's Disease” disclosed 4/8/2019, and h) D-2020-060 - BACE1 Inhibitory Ligand Molecules against Amyloid Beta-induced Synaptic and Mitochondrial Toxicities. 

He served on several review panels and committees, outside the Ƶ, including:  a) Regular member of the NIH Neuronal Oxidative Metabolism and Death Study Section (2013-2019).  At Ƶ, he served as a - a) Member of the Ƶ Faculty Development Leave Committee (2015-2018), b) Member and Chair of the SOM-Ƶ Research Executive Committee (2016-2019), c) Member of the Ƶ Medical Students Promotion Committee (2016-2019), d) Member of the University Research Council (2017-2018), and e) Member of the Ƶ Post Tenure Committee (2018-2020).

Dr. Reddy supervised/mentored over 120 interns/students/postdoctoral fellows/junior faculty.  At least 10 of his postdoctoral fellows are faculty members and/or working in established pharmaceutical companies in the US and abroad. Most recently, Dr. Reddy’s postdoctoral Fellow Dr. Subodh Kumar received a 5-year Career Development Award from NIA/NIH. Dr. Reddy is also co-mentor for another postdoctoral fellow, Dr. Rebecca M. Parodi-Rullán from Temple University who recently awarded her Career Development Award (July 1, 2023 to Jun 30, 2025 (K99). 

He trained over 25 medical students in the last 10 years at Ƶ, these students are authors and co-authors in high-impact factor journals and are matched at the best residency programs in the US. In 2020 alone, 6 medical students (years 1-3) worked with Dr. Reddy in conducting research in the lab and/or writing articles. The major focus of 2020 medical students' research was on COVID-19.  

Dr. Reddy strongly supports women in science and currently, the Reddy Lab has more women scientists than men scientists at all levels; postdoctoral scientists, technicians, students, and interns. We believe this is a wonderful accomplishment, and we recognize the need for more women in Science Technology, Engineering, and Mathematics (STEM). Reddy and his colleagues encourage and strongly support women in science. The Reddy lab is committed to ensuring flexibility and an encouraging environment for women in science. We ensure that our scientists can flex out to balance their work-life schedule as long they are happy and enjoy their work. Dr. Reddy and lab colleagues are proud to see a FIRST WOMEN PRESIDENT, Dr. Lori Rice-Spearman at Ƶ. 

He has over 24 years of research and leadership experience.  He enjoys teaching & researching neurological diseases and truly believes that in his lifetime, significant therapeutic developments will improve the lives of persons with neurological diseases and their caretakers.  Dr. Reddy also enjoys managing large organizations, which led to developing and maintaining a large network of colleagues in research, education, and government regulation. 

Dr. Reddy's research interests are – Drug Discovery, Healthy Aging, MicroRNAs, Synapse, Mitochondria, Oxidative Stress, Neurodegenerative Diseases including Alzheimer's, Huntington's Parkinson's, Multiple Sclerosis, Diabetes/Obesity, Multiple Sclerosis, Depression, Gender-based Studies, Biomarker Development, Bioinformatics and Gene Expression Analysis, and Animal models.

     2021

      • Reddy PH. . Presented at the University of Missouri, Columbia, November 16, 2021.

     2019

      • Kumar S, Reddy PA, Yin X and Reddy PH. Novel microRNA-455-3p and its protective effects against abnormal APP processing and amyloid beta toxicity in Alzheimer’s disease. Poster presented at the Annual Meeting of Society for Neuroscience, Chicago, October 19-23, 2019.
      • Vijayan M and Reddy PH (2019) Novel microRNA PC-5P-12969 and ischemic stroke. Poster presented at the Annual Meeting of Society for Neuroscience, Chicago, October 19-23, 2019.
      • Pradeepkiran JA and Reddy PH (2019) Structure based design and molecular docking studies for phosphorylated tau inhibitors in Alzheimer’s disease. Poster presented at the Annual Meeting of Society for Neuroscience, Chicago, October 19-23, 2019.
      • Invited plenary presentation ‘Early Cellular Changes in Alzheimer’s Disease’ at the International Conference on Neurological Diseases and Therapeutics, Gandhinagar, India, organized by National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad.
      • Invited talk ‘Protective Role of Reduced Drp1 in Alzheimer’s Disease’ by Dr. Kim Tieu, Florida International University, March 28, 2019.
      • Invited talk ‘MicroRNAs as Early Detectable Biomarkers for Alzheimer’s Disease and Ischemic Stroke’ by Dr. H Lee, University of Texas, San Antonio, Feb 4, 2019.

Click here for a complete list of Dr. Reddy's presentations.

  1. John A, Kubosumi A and Reddy PH (2020) Mitochondrial MicroRNAs in Aging and Neurodegenerative Diseases. Cells. 2020 May 28;9(6):E1345. doi: 10.3390/cells9061345.
  2. Khan H, Reddy PH et al. (2020) Gender Differences in Prevalence of Myocardial Infarction in Rural West Texans. Published online May 18, Journal of Public Health, From theory to Practice.
  3. Vijayan M and Reddy PH (2020) Non-Coding RNAs Based Molecular Links in Type 2 Diabetes, Ischemic Stroke, and Vascular Dementia. Journal of Alzheimer’s Disease, J Alzheimers Dis. 2020;75(2):353-383. doi: 10.3233/JAD-200070.
  4. Bhatti G, Reddy AP, Reddy PH and Bhatti J (2019) Lifestyle modifications and nutritional interventions in aging- associated cognitive decline and Alzheimer’s disease. Frontiers in Aging Neuroscience. Front Aging Neurosci. 2020 Jan 10;11:369. doi: 10.3389/fnagi.2019.00369. eCollection 2019.
  5. Pradeepkiran JA, Reddy AP, Yin X, Manczak M, Reddy PH. Protective Effects of BACE1 Inhibitory Ligand Molecules Against Amyloid Beta-Induced Synaptic and Mitochondrial Toxicities in Alzheimer's Disease. Hum Mol Genet. 2020 Jan 1;29(1):49-69. doi: 10.1093/hmg/ddz227.
  6. Reddy PH. Current status of stem cell research: An editorial. Biochim Biophys Acta Mol Basis Dis. 2020 Apr 1;1866(4):165635. doi: 10.1016/j.bbadis.2019.165635.PubMed PMID: 31862303.
  7. Mani C, Reddy PH, Palle K. DNA repair fidelity in stem cell maintenance, health, and disease. Biochim Biophys Acta Mol Basis Dis 2020 Apr 1;1866(4):165444. doi: 10.1016/j.bbadis.2019.03.017.
  8. Reddy PH. Lifestyle and Risk Factors of Dementia in Rural West Texas. J Alzheimers Dis. 2019;72(s1):S1-S10. doi: 10.3233/JAD-191280. PubMed PMID: 31884491.
  9. Khan H, Rafiq A, Shabaneh O, Gittner L and Reddy PH (2019) Current Issues in Chronic Diseases: A Focus on Dementia and Hypertension in Rural West Texans. J Alzheimers Dis. 2019;72(s1):S59-S69. doi: 10.3233/JAD-190893.
  10. Hegde V, Dhurandhar N and Reddy PH (2019) Hyperinsulinemia or Insulin Resistance. What Impacts the progression of Alzheimer's Disease. J Alzheimers Dis. 2019;72(s1):S71-S79. doi: 10.3233/JAD-190808.
  11. Sawant N and Reddy PH (2019) Role of Phosphorylated Tau in Huntington’s Disease Progression J Alzheimers Dis. 2019;72(s1):S177-S191. doi: 10.3233/JAD-190851.
  12. Hegde V, Vijayan M, Kumar S, Akheruzzaman M, Sawant N, Dhurandhar NV, Reddy PH. Adenovirus 36 improves glycemic control and markers of Alzheimer's disease pathogenesis. Biochim Biophys Acta Mol Basis Dis. 2019; 1865(11):165531. doi: 10.1016/j.bbadis.2019.08.007.
  13. Kim Y, Gonzales JU, Reddy PH. An Investigation of Short-Term Longitudinal Associations Between Handgrip Strength and Cardiovascular Disease Biomarkers Among Middle-Aged to Older Adults: A Project FRONTIER Study. J Aging Phys Act. 2020 Jan 1;28(1):9-17. doi: 10.1123/japa.2018-0399.
  14. Vijayan M, Alamri FF, Al Shoyaib A, Karamyan VT, Reddy PH. Novel miRNA PC-5P-12969 in Ischemic Stroke. Mol Neurobiol. 2019; 56(10):6976-6985. doi: 10.1007/s12035-019-1562-x.
  15. Kumar S, Reddy PH. A New Discovery of MicroRNA-455-3p in Alzheimer's Disease. J Alzheimers Dis. 2019;72(s1):S117-S130. doi: 10.3233/JAD-190583.
  16. Kumar S, Reddy AP, Yin X, Reddy PH. Novel MicroRNA-455-3p and its protective effects against abnormal APP processing and amyloid beta toxicity in Alzheimer's disease. Biochim Biophys Acta Mol Basis Dis. 2019; 1865(9):2428-2440. doi: 10.1016/j.bbadis.2019.06.006.
  17. Tamarai K, Bhatti JS, Reddy PH. Molecular and cellular bases of diabetes: Focus on type 2 diabetes mouse model-TallyHo. Biochim Biophys Acta Mol Basis Dis. 2019;1865(9):2276-2284. doi: 10.1016/j.bbadis.2019.05.004.
  18. Oliver D, Reddy PH. Dynamics of Dynamin-Related Protein 1 in Alzheimer's Disease and Other Neurodegenerative Diseases. Cells. 2019; 8(9). pii: E961. doi: 10.3390/cells8090961.
  19. Ramasubramanian B, Reddy PH. Are TallyHo Mice A True Mouse Model for Type 2 Diabetes and Alzheimer's Disease? J Alzheimers Dis. 2019. doi: 10.3233/JAD-190613.
  20. Hegde V, Vijayan M, Kumar S, Akheruzzaman M, Sawant N, Dhurandhar NV, Reddy PH. Adenovirus 36 improves glycemic control and markers of Alzheimer's disease pathogenesis. Biochim Biophys Acta Mol Basis Dis. 2019; 1865(11):165531. doi: 10.1016/j.bbadis.2019.08.007
  21. Gamage S, Peddibhotla S, Reddy PH, Dhurandhar NV, Hegde V. Improvement in Glycemic Control in Mice of Different Age Groups. Exp Clin Endocrinol Diabetes. 2019. doi: 10.1055/a-0961-7804.
  22. George EK, Reddy PH. Can Healthy Diets, Regular Exercise, and Better Lifestyle Delay the Progression of Dementia in Elderly Individuals? J Alzheimers Dis. 2019;72(s1):S37-S58. doi: 10.3233/JAD-190232.
  23. Reddy PH, Oliver DM. Amyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer's Disease. Cells. 2019;8(5). pii: E488. doi: 10.3390/cells8050488.